Kenvue Inc. (NYSE:KVUE) Shares Acquired by OLD National Bancorp IN

OLD National Bancorp IN boosted its position in Kenvue Inc. (NYSE:KVUE) by 14.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,971 shares of the company’s stock after purchasing an additional 2,927 shares during the quarter. OLD National Bancorp IN’s holdings in Kenvue were worth $490,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Grove Bank & Trust raised its position in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at $29,000. Riverview Trust Co purchased a new position in shares of Kenvue during the 3rd quarter worth $30,000. Fortitude Family Office LLC boosted its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue in the third quarter valued at $35,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE stock opened at $21.29 on Friday. The stock has a 50-day simple moving average of $21.90 and a 200-day simple moving average of $21.89. The firm has a market cap of $40.82 billion, a P/E ratio of 38.71, a price-to-earnings-growth ratio of 2.05 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $0.31 earnings per share. On average, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.85%. Kenvue’s payout ratio is currently 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Barclays lowered their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.